India tightens drug safety rules after contaminated medicines spark global outrage

India’s drug regulator has tightened rules on pharmacovigilance and drug safety monitoring for pharmaceutical companies. The Central Drugs Standard Control Organisation (CDSCO) issued a new directive to strengthen oversight following concerns over contaminated medicines linked to child deaths abroad. Manufacturers must now ensure stricter compliance with quality and reporting standards. The updated requirements come under Schedule M, which outlines Good Manufacturing Practices (GMP) for Indian drugmakers. This includes stricter norms for tracking and reporting adverse drug reactions (ADRs). Every licence holder must now maintain a system to collect, process, and forward ADR reports from their products.

The CDSCO’s move follows recent incidents where contaminated cough syrups were tied to multiple child fatalities outside India. These cases exposed gaps in quality control and post-marketing surveillance, prompting regulators to act. Under the new rules, officers from the CDSCO, State Licensing Authorities (SLA), and Union Territory administrations will check compliance during routine inspections. The amendments also align Indian GMP standards more closely with global benchmarks set by the World Health Organization (WHO). Health experts see the directive as a key measure to improve early detection of drug risks. A robust pharmacovigilance system allows regulators to spot safety issues faster, recall faulty products, and prevent large-scale health crises.

The CDSCO’s latest directive reinforces accountability among drug manufacturers. Companies must now establish and maintain effective systems for monitoring adverse reactions. Regulators will verify compliance through inspections, aiming to prevent future incidents linked to unsafe medicines.